Inhaled insulin using AERx®insulin Diabetes Management System (AERx®iDMS)
- 9 October 2007
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 16 (10) , 1673-1681
Abstract
Diabetes is a chronic, debilitating disease that afflicts millions of people worldwide and poor glycemic control in this disease leads to numerous microvascular and macrovascular complications. There is growing evidence that tight glycemic control prevents the development, and delays the progression, of microvascular complications and possibly macrovascular disease in patients with diabetes. All patients with Type 1 diabetes and many patients with Type 2 diabetes require intensive insulin therapy to achieve optimal glucose control. Although subcutaneous insulin therapy is the mainstay of insulin therapy, there are patients who fear needles and often refuse to start insulin therapy despite suboptimal glucose control. In these patients, inhaled insulin represents a non-invasive, painless method to administer intensive insulin treatment. The Novo Nordisk AS AERx® iDMS (insulin Diabetes Management System) for inhaled insulin is a novel device that administers an aerosol of liquid insulin into the deep lung wi...Keywords
This publication has 22 references indexed in Scilit:
- Inhaled Insulin for Diabetes MellitusNew England Journal of Medicine, 2007
- Resistance to Insulin Therapy Among Patients and ProvidersDiabetes Care, 2005
- Psychological Insulin Resistance in Patients With Type 2 DiabetesDiabetes Care, 2005
- Effects of different durations of breath holding after inhalation of insulin using the AERx® insulin diabetes management systemClinical Therapeutics, 2003
- Pulmonary Insulin Administration Using the AERx ® Insulin Diabetes SystemDiabetes Technology & Therapeutics, 2002
- Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patientsDiabetologia, 2001
- Pulmonary Insulin Administration Using the AERx® System: Physiological and Physicochemical Factors Influencing Insulin Effectiveness in Healthy Fasting SubjectsDiabetes Technology & Therapeutics, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Inhalation delivery systems with compliance and disease management capabilitiesJournal of Controlled Release, 1998
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993